Tradestie Institutional Equity Comparison Engine

LCTX vs SGMT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SGMT Overall Edge

SGMT Captures Institutional Edge (3โ€“1 Pillars ยท 4โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sagimet Biosciences Inc. Series A Common Stock (SGMT) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while LCTX counters with relative strength in Valuation. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus SGMT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LCTX sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against SGMT sits in CONSOLIDATION (82nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
LCTX 30.7x vs SGMT N/M Fwd P/E
Growth & Margin Winner SGMT
Op Margin -280.3% vs 0.0% ยท YoY -61.0% vs +0.0%
Momentum & Technical Winner SGMT
1Y -54.9% vs +15.7% ยท 52W Pos 0% vs 66%
Options & Structure Winner SGMT
BREAKDOWN (<1st %ile IV) vs CONSOLIDATION (82nd %ile IV)
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
1M Return -21.63%
1Y Return -54.86%
Forward P/E 30.7x
Unified AI Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0
SGMT NASDAQ
Sagimet Biosciences Inc. Series A Common Stock
Pharmaceutical Preparations
$9.08
-5.61% 1D
Market Cap $692.0M
1M Return -8.74%
1Y Return +15.67%
Forward P/E N/M
Unified AI Score
44.6 / 100 HOLD
Tech 22.0 Fund 48.0 Flow 70.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LCTX -54.86% SGMT +15.67% Spread: +70.53 pp (SGMT Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LCTX Revenue SGMT Revenue LCTX Op. Margin SGMT Op. Margin Margin Edge
FY2018 $0M N/A -837.9% N/A LCTX
FY2019 $0M N/A -1106.0% N/A LCTX
FY2020 $0M N/A -1448.4% N/A LCTX
FY2021 $0M N/A -1133.6% N/A LCTX
FY2022 $10M N/A -153.2% N/A LCTX
FY2023 $10M $0M -276.5% -1537.0% LCTX
FY2024 $10M N/A -226.1% N/A LCTX
FY2025 $10M N/A -251.6% N/A LCTX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LCTX (6) vs SGMT (4)
Institutional Metric LCTX SGMT Criterion Row Winner
Market Capitalization Scale $207.4M $692.0M Larger Scale SGMT
Trailing P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Forward P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY) Growth -61.0% +0.0% Higher Growth SGMT
Operating Margin (TTM) Profitability -280.3% 0.0% Higher Margin SGMT
Net Profit Margin Profitability 16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency 4.3% -29.5% Higher ROE LCTX
52-Week Range Position Momentum 0% ($1โ€“$2) 66% ($4โ€“$11) Stronger Trend SGMT
Beta / 30D Volatility Risk Regime 1.39ฮฒ ยท 79% Vol 2.04ฮฒ ยท 80% Vol Lower Realized Risk LCTX
Unified Institutional Score Composite Signal 54.9 / 100 (HOLD) 44.6 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LCTX vs SGMT Buy Guide
LCTX BREAKDOWN
7d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SGMT CONSOLIDATION
144d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 82nd %ile
IV Regime Extreme (>80th %ile)
Live SGMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LCTX nor SGMT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.